TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8721800

Group type: EXPERIMENTAL
Intervention: Dietary intervention based on NCEP-ATP I fat-modified step I diet specifications, consisting of five sessions over an 8-week period.
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Pre- and postintervention nutrition data for 20 screenees randomized into the study.
Number of subjects: 77
Study: 1667469

Group type: EXPERIMENTAL
Intervention: Anticalculus dentifrice (1.3% soluble pyrophosphate and 1.5% Gantrez copolymer in a 0.243% sodium fluoride/silica base)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo dentifrice (0.243% sodium fluoride in a silica base)
Number of subjects: 0
Study: 6858922

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 26
Study: 30729554

Group type: EXPERIMENTAL
Intervention: Sensory Adapted Dental Environment (SADE)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Regular Dental Environment (RDE)
Number of subjects: 22
Study: 29206719

Group type: EXPERIMENTAL
Intervention: Urodynamic procedures for mixed and other types of UI
Number of subjects: 1000000

Group type: EXPERIMENTAL
Intervention: Surgical procedures for urge or stress UI
Number of subjects: 1000000

Group type: EXPERIMENTAL
Intervention: Healthcare resource utilization in patients with UI
Number of subjects: 1000000
Study: 26511068

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 8246

Group type: COMPARATOR
Intervention: Enoxaparin/VKAs
Number of subjects: 8246
Study: 25145986

Group type: EXPERIMENTAL
Intervention: House dust mite sublingual immunotherapy (SLIT) with Dermatophagoides farinae extracts for 52 weeks, combined with standard pharmacotherapy.
Number of subjects: 112
Study: 22233697

Group type: EXPERIMENTAL
Intervention: Risperidone oral solution (RIS-OS) plus clonazepam
Number of subjects: 205

Group type: COMPARATOR
Intervention: Intramuscular haloperidol
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Combination treatment (RIS-OS plus clonazepam)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Both treatments after 6-week treatment
Number of subjects: 205
Study: 20059420

Group type: EXPERIMENTAL
Intervention: Subgingival air polishing with a new device
Number of subjects: 50

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP)
Number of subjects: 50
Study: 17077190

Group type: EXPERIMENTAL
Intervention: Ghrelin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peptide YY
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pancreatic polypeptide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glucagon-like peptide-1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxyntomodulin
Number of subjects: 0
Study: 14613759

Group type: EXPERIMENTAL
Intervention: Naringin (400mg/capsule/day) for 8 weeks
Number of subjects: 30
Study: 10753245

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (7 microg/kg/d when fed parenterally and 5 microg/kg/d when fed orally)
Number of subjects: 534

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 534

Group type: EXPERIMENTAL
Intervention: Selenium supplementation
Number of subjects: 534
Study: 8602586

Group type: COMPARATOR
Intervention: BPVEM diet
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: LWF diet
Number of subjects: 14
Study: 1413608

Group type: EXPERIMENTAL
Intervention: Diluted sulfur mud baths
Number of subjects: 16

Group type: COMPARATOR
Intervention: Diluted mud baths without sulfur compounds
Number of subjects: 16
Study: 3880641

Group type: EXPERIMENTAL
Intervention: Trabeculectomy with Healonid injected into the anterior chamber
Number of subjects: 27

Group type: COMPARATOR
Intervention: Trabeculectomy alone
Number of subjects: 27
Study: 31793231

Group type: EXPERIMENTAL
Intervention: Intravenous rezafungin (600 mg and 1400 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moxifloxacin (positive control)
Number of subjects: 0
Study: 30616912

Group type: EXPERIMENTAL
Intervention: Nemonoxacin 500 mg (NEMO-500MG)
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: Nemonoxacin 750 mg (NEMO-750MG)
Number of subjects: 995

Group type: COMPARATOR
Intervention: Levofloxacin 500 mg (LEVO)
Number of subjects: 995
Study: 27845338

Group type: EXPERIMENTAL
Intervention: Internet‐CBT (10-week intervention focused on exposure to IBS symptoms)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Internet‐CBT
Number of subjects: 101

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 101
Study: 25813563

Group type: EXPERIMENTAL
Intervention: Parasacral transcutaneous electrical stimulation
Number of subjects: 28

Group type: COMPARATOR
Intervention: Oxybutynin
Number of subjects: 28
Study: 23276821

Group type: EXPERIMENTAL
Intervention: Carboplatin/paclitaxel/sorafenib
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 21329501

Group type: EXPERIMENTAL
Intervention: Cognitive stimulation therapy (CST) delivered to participants with mild AD and their companions together.
Number of subjects: 128

Group type: COMPARATOR
Intervention: Cognitive stimulation therapy (CST) delivered to companions of participants with mild AD alone.
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Cognitive stimulation therapy (CST) for participants with mild AD and their companions together.
Number of subjects: 128

Group type: COMPARATOR
Intervention: Cognitive stimulation therapy (CST) for companions of participants with mild AD alone.
Number of subjects: 128
Study: 20110015

Group type: EXPERIMENTAL
Intervention: Generic chlorphenesin carbamate 250 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Generic chlorphenesin carbamate 500 mg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Branded chlorphenesin carbamate 250 mg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Branded chlorphenesin carbamate 500 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both formulations (generic and branded)
Number of subjects: 28
Study: 17286150

Group type: EXPERIMENTAL
Intervention: 20 ppm 1,4-dioxane vapour for 2 hours
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control exposure (0 ppm 1,4-dioxane vapour) for 2 hours
Number of subjects: 12
Study: 15385380

Group type: EXPERIMENTAL
Intervention: Femoral nerve block with lidocaine 1.5% 15 mL (group FEM)
Number of subjects: 20

Group type: COMPARATOR
Intervention: IV fentanyl 3 microg/kg (group IVA)
Number of subjects: 20
Study: 11118395

Group type: EXPERIMENTAL
Intervention: Intramuscular route
Number of subjects: 141

Group type: COMPARATOR
Intervention: Subcutaneous route
Number of subjects: 141
Study: 9701523

Group type: EXPERIMENTAL
Intervention: Omeprazole therapy (duration: 80 months for hypergastrinaemia group, 55 months for control group)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Omeprazole therapy
Number of subjects: 26
Study: 8254816

Group type: EXPERIMENTAL
Intervention: RDA multivitamins plus 40,000 units vitamin A, 100 mg. vitamin B6, 2,000 mg. vitamin C, 400 units vitamin E and 90 mg. zinc
Number of subjects: 65

Group type: COMPARATOR
Intervention: RDA multivitamins
Number of subjects: 65
Study: 2572666

Group type: COMPARATOR
Intervention: xamoterol 200 mg b.i.d. for 4 weeks
Number of subjects: 28
Study: 1058527

Group type: EXPERIMENTAL
Intervention: 5 days pretreatment with 1‐asparaginase and prednisolone followed by a combination of rubidomycin and cytosine arabinoside (ARAP)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Treatment with a combination of rubidomycin, cytosine arabinoside and prednisolone without 1‐asparaginase pretreatment (RAP)
Number of subjects: 77
Study: 31130504

Group type: COMPARATOR
Intervention: Hydrocortisone 1% cream
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Triamcinolone 0.1% cream
Number of subjects: 52
Study: 28262319

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid (fluticasone or budesonide) prescribed during ED visit for 1 month in addition to standard asthma therapy.
Number of subjects: 147

Group type: COMPARATOR
Intervention: Standard asthma therapy without inhaled corticosteroid prescription.
Number of subjects: 147
Study: 26059225

Group type: EXPERIMENTAL
Intervention: FF/VI 100/25 μg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: FF/VI 200/25 μg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: FF/VI 50/25 μg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: FF/VI 50/25-200/25 μg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: FF/VI
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 24228710

Group type: EXPERIMENTAL
Intervention: Salmeterol, 50 μg twice a day for 2 weeks
Number of subjects: 26
Study: 21624699

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Number of subjects: 200

Group type: COMPARATOR
Intervention: Simple emollient
Number of subjects: 200
Study: 18774180

Group type: EXPERIMENTAL
Intervention: Quetiapine 300 mg/day
Number of subjects: 1051

Group type: EXPERIMENTAL
Intervention: Quetiapine 600 mg/day
Number of subjects: 1051

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1051
Study: 16702815

Group type: EXPERIMENTAL
Intervention: 9-aminocamptothecin (9-AC) with DMA formulation, 6.2 to 10.60 mg/m/cycle for 7-21 days
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 9-aminocamptothecin (9-AC) with CD formulation, 12.60 mg/m/cycle for 21 days
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 9-aminocamptothecin (9-AC) with CD formulation, 9.44 to 12.60 mg/m/cycle for 14 days
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 9-aminocamptothecin (9-AC)
Number of subjects: 62
Study: 12620439

Group type: EXPERIMENTAL
Intervention: Transdermal E(2) patch
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Transdermal E(2) gel
Number of subjects: 122
Study: 11762805

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (ciprofloxacin 750 mg plus roxithromycin 150 mg, bid. days 4-13)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (ciprofloxacin plus roxithromycin)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 9048239

Group type: EXPERIMENTAL
Intervention: Norethindrone acetate (10 mg) with leuprolide acetate (1 mg)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Leuprolide acetate (1 mg) alone
Number of subjects: 41
Study: 8106151

Group type: EXPERIMENTAL
Intervention: Spiradoline (1 to 4 micrograms/kg)
Number of subjects: 4
Study: 3219974

Group type: EXPERIMENTAL
Intervention: Antitumor B (Chinese herbs)
Number of subjects: 6758

Group type: EXPERIMENTAL
Intervention: Retinamide (4‐Ethoxycarbophenylretinamide)
Number of subjects: 6758

Group type: EXPERIMENTAL
Intervention: Riboflavin
Number of subjects: 6758

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6758
Study: 31902472

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 283

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 283
Study: 29605753

Group type: EXPERIMENTAL
Intervention: Intervention group 1 - midwifery intervention involving oral health education, screening and referrals to existing dental pathways
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Intervention group 2 - midwifery intervention plus dental intervention involving assessment/treatment from cost free local dental services
Number of subjects: 638

Group type: COMPARATOR
Intervention: Control group - received oral health information at recruitment
Number of subjects: 638
Study: 28864871

Group type: EXPERIMENTAL
Intervention: Eltrombopag 100 mg
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 25239521

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel (135 mg/m2, d1, 8, q3w) plus carboplatin (AUC 5, d1, q3w)
Number of subjects: 120

Group type: COMPARATOR
Intervention: gemcitabine (1,250 mg/m2, d1, 8, q3w) plus carboplatin (AUC 5, d1, q3w)
Number of subjects: 120
Study: 22246377

Group type: EXPERIMENTAL
Intervention: Exenatide (0.12 pmol/kg/min) infusion for 6 hours
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo infusion for 6 hours
Number of subjects: 20
Study: 20436265

Group type: EXPERIMENTAL
Intervention: E₂/DSP
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: E₂/NETA
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: tibolone
Number of subjects: 106
Study: 16777467

Group type: EXPERIMENTAL
Intervention: Accessory knee joint mobilization (9-min, non-noxious, AP mobilization of the tibio-femoral joint)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Manual contact (control)
Number of subjects: 38

Group type: COMPARATOR
Intervention: No-contact (control)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Accessory knee joint mobilization
Number of subjects: 38
Study: 16223397

Group type: EXPERIMENTAL
Intervention: Vertical infraclavicular approach
Number of subjects: 60

Group type: COMPARATOR
Intervention: Axillary approach
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 60
Study: 12141068

Group type: EXPERIMENTAL
Intervention: Raloxifene (30, 60 or 150 mg day-1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Levormeloxifene (1.25, 5, 10 or 20 mg day-1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 10211854

Group type: EXPERIMENTAL
Intervention: Squat Jump (SJ) protocol
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Countermovement Jump (CMJ) data
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Cross-validation using PRESS
Number of subjects: 108
Study: 7843430

Group type: EXPERIMENTAL
Intervention: 150 IU IM FSH with or without 75 IU SC hCG
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 225 IU FSH with or without 50 IU SC hCG
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 150 or 225 IU IM hMG
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: SC mini-dose hCG
Number of subjects: 32
Study: 2388642

Group type: EXPERIMENTAL
Intervention: Modified inverted walking stick (VC stick)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Straight walking stick
Number of subjects: 8

Group type: COMPARATOR
Intervention: Parallel lines spaced every 12 in.
Number of subjects: 8
Study: 571216

Group type: EXPERIMENTAL
Intervention: 25% salt‐poor human albumin (1.5 ml/kg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma (7 ml/kg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 0.9% NaCl in water (normal saline) (7 ml/kg)
Number of subjects: 15
Study: 30796020

Group type: EXPERIMENTAL
Intervention: 3+0 schedule pneumococcal conjugate vaccine (PCV13)
Number of subjects: 402
Study: 27598855

Group type: EXPERIMENTAL
Intervention: Epratuzumab 600 mg every week
Number of subjects: 1584

Group type: EXPERIMENTAL
Intervention: Epratuzumab 1200 mg every other week
Number of subjects: 1584

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1584
Study: 26051574

Group type: EXPERIMENTAL
Intervention: Prolotherapy (hypertonic dextrose injection)
Number of subjects: 65
Study: 23659362

Group type: EXPERIMENTAL
Intervention: 3DSTE in patients with AF
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 20
Study: 21034693

Group type: EXPERIMENTAL
Intervention: citalopram + pindolol (5 mg tid)
Number of subjects: 30

Group type: COMPARATOR
Intervention: citalopram + placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: pindolol (meta-analysis)
Number of subjects: 30
Study: 19425356

Group type: EXPERIMENTAL
Intervention: Personal goals (autonomous interest)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vertical goals (social expectation)
Number of subjects: 0
Study: 17545881

Group type: EXPERIMENTAL
Intervention: Exercise intervention (2-4 times per week for 6 months)
Number of subjects: 561
Study: 17416939

Group type: EXPERIMENTAL
Intervention: Latanoprost monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Timolol/dorzolamide combination therapy
Number of subjects: 0
Study: 14657813

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 16 to 32 mg/kg/d for 6 days
Number of subjects: 391

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 391
Study: 10609908

Group type: EXPERIMENTAL
Intervention: Papaverin 2 mg/ml
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Nitroglycerin 1 mg/ml
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Verapamil 0.5 mg/ml
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Nitroprusside 0.5 mg/ml
Number of subjects: 80

Group type: COMPARATOR
Intervention: Normal saline 0.9% (placebo)
Number of subjects: 80
Study: 7815628

Group type: EXPERIMENTAL
Intervention: Artery sparing techniques
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Palomo procedure
Number of subjects: 88

Group type: COMPARATOR
Intervention: Uncorrected varicoceles (comparison group)
Number of subjects: 88
Study: 2014087

Group type: EXPERIMENTAL
Intervention: Short-term cefoxitin prophylaxis (3 doses)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Long-term cefoxitin prophylaxis (12 doses)
Number of subjects: 113
Study: 7049077

Group type: EXPERIMENTAL
Intervention: Clofazimine (200 mg daily for 5 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clofazimine (concentration range 5 X 10(‐6) M to 5 X 10(‐3) M)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clofazimine with dapsone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clofazimine (after ingestion)
Number of subjects: 0
Study: 31116261

Group type: EXPERIMENTAL
Intervention: 200 mg/day adjunctive minocycline for MDD
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 30672619

Group type: EXPERIMENTAL
Intervention: Carbohydrate ingestion (8% maltodextrin, CHO) during exercise
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo ingestion (0% carbohydrate, PLA) during exercise
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Carbohydrate ingestion during exercise
Number of subjects: 9
Study: 27887769

Group type: COMPARATOR
Intervention: DPPOS participants
Number of subjects: 0
Study: 25952728

Group type: EXPERIMENTAL
Intervention: Aclidinium 400µg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Glycopyrronium 50μg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Tiotropium 18µg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Glycopyrronium (10nM, 100nM, 1μM)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Aclidinium (1μM)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Tiotropium (1μM)
Number of subjects: 16
Study: 23154591

Group type: EXPERIMENTAL
Intervention: valsartan add-on group
Number of subjects: 303

Group type: COMPARATOR
Intervention: conventional therapy without ARB (control group)
Number of subjects: 303
Study: 21252014

Group type: EXPERIMENTAL
Intervention: BIOBYPASS (AdGVVEGF121.10NH) gene therapy
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 18302016

Group type: EXPERIMENTAL
Intervention: CTC prevention framework implementation monitoring system
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CTC program implementation monitoring system
Number of subjects: 12
Study: 16442668

Group type: EXPERIMENTAL
Intervention: Meal foods
Number of subjects: 0

Group type: COMPARATOR
Intervention: Snack foods
Number of subjects: 0
Study: 12769153

Group type: EXPERIMENTAL
Intervention: ReNu Multi Plus
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: OPTI‐FREE Express
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Complete Blink‐N‐Clean
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lens Plus
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no drops during recovery)
Number of subjects: 20
Study: 11125686

Group type: EXPERIMENTAL
Intervention: Isoflurane 3.0%
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Esmolol 2 mg/kg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intravenous saline
Number of subjects: 30
Study: 9235523

Group type: EXPERIMENTAL
Intervention: C-reactive protein
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Fibrinogen
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Component C3 of complement
Number of subjects: 95

Group type: COMPARATOR
Intervention: Transient ischaemic attack
Number of subjects: 95
Study: 1610165

Group type: EXPERIMENTAL
Intervention: Meal offered 60 min after exercise
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Meal offered at random intervals (0, 30, 60, or 120 min after exercise)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Meal offered 60 min after a session without exercise
Number of subjects: 13
Study: 3933035

Group type: EXPERIMENTAL
Intervention: Fluphenazine enanthate (25 mg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate (25 mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 7
Study: 29928114

Group type: EXPERIMENTAL
Intervention: LCB01-0371 under fed condition
Number of subjects: 18

Group type: COMPARATOR
Intervention: LCB01-0371 under fasting condition
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: LCB01-0371 under fed and fasting conditions
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: LCB01-0371
Number of subjects: 18
Study: 26426458

Group type: EXPERIMENTAL
Intervention: Apneic oxygenation (15 L/min of 100% oxygen via high-flow nasal cannula during laryngoscopy)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual care (no supplemental oxygen during laryngoscopy)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Apneic oxygenation
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Apneic oxygenation and usual care
Number of subjects: 150
Study: 24630848

Group type: EXPERIMENTAL
Intervention: Anodal TDCS at 2 mA
Number of subjects: 53

Group type: COMPARATOR
Intervention: Cathodal TDCS at 2 mA
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Both forms of stimulation (anodal and cathodal)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Latency difference of MEPs (anterior‐posterior stimulation minus latero‐medial stimulation)
Number of subjects: 53
Study: 23681467

Group type: EXPERIMENTAL
Intervention: Intramedullary nailing (IMN)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Open reduction internal fixation (ORIF)
Number of subjects: 50
Study: 19841160

Group type: EXPERIMENTAL
Intervention: lisinopril 10 to 20 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: lisinopril 10 to 20 mg/d plus simvastatin 20 mg/d
Number of subjects: 0
Study: 18764914

Group type: EXPERIMENTAL
Intervention: Lung resection (lobectomy or pneumonectomy)
Number of subjects: 2
Study: 17064591

Group type: EXPERIMENTAL
Intervention: SELDI‐TOF‐MS protein fingerprinting in serum
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: m/z 3078.7 biomarker
Number of subjects: 39